Aevitas Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Aevitas Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-300	Closed	-$11K	–	264
2019 Q1	$11K	Hold	300	–	–	0.01%	297
2018 Q4	$13K	Hold	300	–	–	0.01%	282
2018 Q3	$15K	Hold	300	–	–	0.01%	311
2018 Q2	$10K	Hold	300	–	–	0.01%	330
2018 Q1	$9K	Buy	+300	New	+$10.7K	0.01%	334

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aevitas Wealth Management's PCRX Position: Q2 2019 in Review

Aevitas Wealth Management sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 300 shares — an estimated $11K sold.

Aevitas Wealth Management first reported a position in PCRX in Q1 2018 and held it in 5 quarters. The position peaked at $15K in Q3 2018. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

Aevitas Wealth Management reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
Aevitas Wealth Management sold 300 Pacira BioSciences shares in Q2 2019, an estimated $11K.
Aevitas Wealth Management first reported a position in Pacira BioSciences in Q1 2018 and held it in 5 quarters.
Aevitas Wealth Management's Pacira BioSciences position peaked at $15K in Q3 2018.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.